Business UpdateJun 2, 2026, 07:32 AM
Optimi Health Completes Psilocybin Production for Australia & Trials
AI Summary
Optimi Health Corp. announced the completion of a GMP production run for its 5mg psilocybin finished drug product. These capsules are already prescribed commercially in Australia for treatment-resistant depression, with an updated bottling configuration for improved ease of use. Additional product from this run is designated for upcoming clinical research in the United States and clinical trials in Europe across various indications. The entire manufacturing process, from biomass cultivation to packaging, was completed in-house under Optimi's Health Canada Drug Establishment Licence.
Key Highlights
- Completed GMP production run of 5mg psilocybin finished drug product.
- Psilocybin capsules are prescribed commercially in Australia for treatment-resistant depression.
- Additional product earmarked for clinical research in the US and clinical trials in Europe.
- Manufacturing completed in-house under Health Canada Drug Establishment Licence (DEL).
- Facility authorized to hold up to 20 kg of psilocybin and 2,000 kg of biomass.
- Optimi is a vertically integrated GMP supply layer for regulated psychedelic medicine.
Price Impact
More from OPTH